Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report

Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed follow...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Annals of translational medicine Ročník 7; číslo 5; s. 106
Hlavní autoři: Bender, Laura, Meyer, Guillaume, Quoix, Elisabeth, Mennecier, Bertrand
Médium: Journal Article
Jazyk:angličtina
Vydáno: China 01.03.2019
Témata:
Anaplastic lymphoma kinase rearrangement (ALK rearrangement)
diffuse interstitial pneumonitis
ceritinib
non-small cell lung cancer (NSCLC)
ISSN:2305-5839, 2305-5839
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.
AbstractList Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.
Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.
Author Meyer, Guillaume
Quoix, Elisabeth
Mennecier, Bertrand
Bender, Laura
Author_xml – sequence: 1
  givenname: Laura
  surname: Bender
  fullname: Bender, Laura
  organization: Department of Medical Oncology, University Hospital, Strasbourg, France
– sequence: 2
  givenname: Guillaume
  surname: Meyer
  fullname: Meyer, Guillaume
  organization: Department of Pharmacy, University Hospital, Strasbourg, France
– sequence: 3
  givenname: Elisabeth
  surname: Quoix
  fullname: Quoix, Elisabeth
  organization: Department of Pneumology, University Hospital, Strasbourg, France
– sequence: 4
  givenname: Bertrand
  surname: Mennecier
  fullname: Mennecier, Bertrand
  organization: Department of Pneumology, University Hospital, Strasbourg, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31019956$$D View this record in MEDLINE/PubMed
BookMark eNpNUE1PwzAMjdAQG2NnbihHLi35aLqGG5r4kiZxgXOVpO4IatORpCD4I_xdwhgSJ9vPz372O0YTNzhA6JSSnFHClxcq9jkjVOaE5qw4QDPGichExeXkXz5FixBeCCGUUckJOUJTTtOUFOUMfa3A22id1ZmHTkVosHURfIgJVR3uRrfBjQ2gAmDbb_3wZhOi2sTB0UM6AVzEBkJQ0Q4Ov9v4PIwRezCj9-AM4NE1iQypkYLx9nPYCeLBY-3tRu2qS6yw-RHxsB18PEGHreoCLPZxjp5urh9Xd9n64fZ-dbXODK9kzEoll7yVQhayYG0piKqkJpqD1MIwLnVlklWm5ULTQvFCsqZRpS6l0G2bPGBzdP67N332OkKIdW-Dga5TDoYx1IxRQWhFOEvUsz111D009dbbXvmP-s9M9g0_Sn0c
CitedBy_id crossref_primary_10_1002_cam4_5913
crossref_primary_10_1007_s11095_020_02851_7
crossref_primary_10_1111_1759_7714_13416
crossref_primary_10_1007_s11523_020_00733_x
crossref_primary_10_1016_j_cpccr_2020_100023
crossref_primary_10_1007_s40278_019_60943_7
crossref_primary_10_1016_j_cllc_2020_06_021
crossref_primary_10_3389_fonc_2025_1572425
crossref_primary_10_20473_jr_v11_I_1_2025_83_92
ContentType Journal Article
DBID NPM
7X8
DOI 10.21037/atm.2019.01.24
DatabaseName PubMed
MEDLINE - Academic
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 2305-5839
ExternalDocumentID 31019956
Genre Case Reports
GroupedDBID 53G
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
HYE
M~E
NPM
OK1
RPM
7X8
ID FETCH-LOGICAL-c389t-6a973f9594942f650a89b0b3e9b5c239b8c210cf35b14a3492dda6b695bff0192
IEDL.DBID 7X8
ISICitedReferencesCount 9
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000461023500028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2305-5839
IngestDate Thu Jul 10 22:55:48 EDT 2025
Thu Jan 02 23:05:07 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 5
Keywords Anaplastic lymphoma kinase rearrangement (ALK rearrangement)
diffuse interstitial pneumonitis
ceritinib
non-small cell lung cancer (NSCLC)
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c389t-6a973f9594942f650a89b0b3e9b5c239b8c210cf35b14a3492dda6b695bff0192
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
OpenAccessLink https://atm.amegroups.com/article/viewFile/23669/pdf
PMID 31019956
PQID 2215018032
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2215018032
pubmed_primary_31019956
PublicationCentury 2000
PublicationDate 2019-Mar
20190301
PublicationDateYYYYMMDD 2019-03-01
PublicationDate_xml – month: 03
  year: 2019
  text: 2019-Mar
PublicationDecade 2010
PublicationPlace China
PublicationPlace_xml – name: China
PublicationTitle Annals of translational medicine
PublicationTitleAlternate Ann Transl Med
PublicationYear 2019
SSID ssj0001219300
Score 2.1378589
Snippet Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 106
Title Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report
URI https://www.ncbi.nlm.nih.gov/pubmed/31019956
https://www.proquest.com/docview/2215018032
Volume 7
WOSCitedRecordID wos000461023500028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXI3gN2s2-4kWkWDzY0oNKbyXJJlCQ3brdevCP-HedyW7ViyB4WdjDkiWZTL7MzPcNYxdkBaSUxvHo1Ty0JHmbJZYLba3RGXoH34vg-SEZDNLRSA6bgNusKatc-ETvqLPCUIz8MsCzicSmRHAzfeXUNYqyq00LjWXWEghlqKQrGaU_YiwITzwLBYF2RAQjWav7BF7XR1VERe9I0u0kxvtvENMfNb3N__7kFttoQCbc1laxzZZsvsPW-k0afZd9dC1pGeUTzT2XxWZAshEl1Q2gPcILegBoUjcwWYQdwPcTh6_SdCCGgV9YoGhuMa-gpOi95w8CkdNKsET5KAFd03vhB4SiBF16XQ98uwYFhgapUxd77Kl399i9502HBm4Q6FQ8VjIRTkYylGHgEOypVOorLazUkQmE1KnBqTZORLoTKhJCzDIV61hG2jkCl_tsJS9ye8gAgV8irIqNMgjhHF4js1CkSehiuiQlnTY7X0z5GHcApTVUbov5bPw96W12UK_beFpLdYwRvBIHPT76w9fHbJ2soS4wO2Eth_vfnrJV81ZNZuWZNy18Dob9T-wf2z4
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ceritinib-related+interstitial+lung+disease+improving+after+treatment+cessation+without+recurrence+under+either+crizotinib+or+brigatinib%3A+a+case+report&rft.jtitle=Annals+of+translational+medicine&rft.au=Bender%2C+Laura&rft.au=Meyer%2C+Guillaume&rft.au=Quoix%2C+Elisabeth&rft.au=Mennecier%2C+Bertrand&rft.date=2019-03-01&rft.issn=2305-5839&rft.eissn=2305-5839&rft.volume=7&rft.issue=5&rft.spage=106&rft_id=info:doi/10.21037%2Fatm.2019.01.24&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2305-5839&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2305-5839&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2305-5839&client=summon